NZ722025A - Beta-hairpin peptidomimetics as selective elastase inhibitors - Google Patents

Beta-hairpin peptidomimetics as selective elastase inhibitors

Info

Publication number
NZ722025A
NZ722025A NZ722025A NZ72202513A NZ722025A NZ 722025 A NZ722025 A NZ 722025A NZ 722025 A NZ722025 A NZ 722025A NZ 72202513 A NZ72202513 A NZ 72202513A NZ 722025 A NZ722025 A NZ 722025A
Authority
NZ
New Zealand
Prior art keywords
diseases
infections
xaa11
xaa12
xaa13
Prior art date
Application number
NZ722025A
Other languages
English (en)
Inventor
Daniel Obrecht
Frank Gombert
Alexander Lederer
Odile Sellier-Kessler
Christian Ludin
Manuella Schmitt-Billet
Steffen Weinbrenner
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of NZ722025A publication Critical patent/NZ722025A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NZ722025A 2013-12-27 2013-12-27 Beta-hairpin peptidomimetics as selective elastase inhibitors NZ722025A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/078073 WO2015096873A1 (en) 2013-12-27 2013-12-27 Beta-hairpin peptidomimetics as selective elastase inhibitors

Publications (1)

Publication Number Publication Date
NZ722025A true NZ722025A (en) 2019-06-28

Family

ID=49911533

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ722025A NZ722025A (en) 2013-12-27 2013-12-27 Beta-hairpin peptidomimetics as selective elastase inhibitors

Country Status (25)

Country Link
US (1) US10273267B2 (enExample)
EP (1) EP3087094B1 (enExample)
JP (1) JP6499183B2 (enExample)
KR (1) KR102214694B1 (enExample)
CN (1) CN106029689B (enExample)
AU (1) AU2013409200B2 (enExample)
BR (1) BR112016014916B1 (enExample)
CA (1) CA2933660C (enExample)
DK (1) DK3087094T3 (enExample)
EA (1) EA201691330A1 (enExample)
ES (1) ES2925747T3 (enExample)
HR (1) HRP20221046T1 (enExample)
HU (1) HUE059846T2 (enExample)
IL (1) IL246175B (enExample)
LT (1) LT3087094T (enExample)
MX (1) MX389053B (enExample)
NZ (1) NZ722025A (enExample)
PL (1) PL3087094T3 (enExample)
PT (1) PT3087094T (enExample)
RS (1) RS63543B1 (enExample)
SG (1) SG11201605122WA (enExample)
SI (1) SI3087094T1 (enExample)
SM (1) SMT202200393T1 (enExample)
WO (1) WO2015096873A1 (enExample)
ZA (1) ZA201604821B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0721259C1 (pt) 2007-02-28 2021-05-25 Polyphor Ltd composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto
CN105873939B (zh) * 2013-12-27 2021-08-27 波利弗尔股份公司 作为选择性弹性蛋白酶抑制剂的β-发夹肽模拟物
US10676723B2 (en) * 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11201802777XA (en) 2015-10-14 2018-05-30 X Therma Inc Compositions and methods for reducing ice crystal formation
ES2928050T3 (es) 2016-05-31 2022-11-15 Spexis Ag Peptidomimético de horquilla beta con actividad inhibidora de elastasa y formas de dosificación en aerosol del mismo
BR112022004861A2 (pt) 2019-09-17 2022-06-07 Univ Duke Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro
US20230190723A1 (en) 2020-04-16 2023-06-22 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
CN114573686A (zh) * 2020-11-30 2022-06-03 中国医学科学院药物研究所 含有二硫键且具有抑制丝氨酸蛋白酶活性的多肽及其应用
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
GB9825854D0 (en) 1998-11-25 1999-01-20 Univ Bristol Peptide
CN101157924A (zh) 2001-12-11 2008-04-09 人体基因组科学有限公司 嗜中性白细胞因子α
CA2915175C (en) * 2005-02-17 2019-04-09 Polyphor Ltd. Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity
CN105873939B (zh) * 2013-12-27 2021-08-27 波利弗尔股份公司 作为选择性弹性蛋白酶抑制剂的β-发夹肽模拟物

Also Published As

Publication number Publication date
BR112016014916A2 (enExample) 2017-08-08
SMT202200393T1 (it) 2022-11-18
IL246175A0 (en) 2016-07-31
EP3087094A1 (en) 2016-11-02
CN106029689B (zh) 2021-09-28
EP3087094B1 (en) 2022-06-01
ZA201604821B (en) 2017-09-27
PT3087094T (pt) 2022-09-05
ES2925747T3 (es) 2022-10-19
AU2013409200B2 (en) 2019-08-15
EA201691330A1 (ru) 2016-10-31
RS63543B1 (sr) 2022-09-30
IL246175B (en) 2022-04-01
MX389053B (es) 2025-03-20
WO2015096873A1 (en) 2015-07-02
AU2013409200A1 (en) 2016-07-21
MX2016008318A (es) 2016-10-13
US20160333053A1 (en) 2016-11-17
KR20160102313A (ko) 2016-08-29
JP2017504620A (ja) 2017-02-09
SG11201605122WA (en) 2016-07-28
US10273267B2 (en) 2019-04-30
CN106029689A (zh) 2016-10-12
SI3087094T1 (sl) 2022-11-30
LT3087094T (lt) 2022-09-26
HUE059846T2 (hu) 2023-01-28
HRP20221046T1 (hr) 2023-01-20
DK3087094T3 (da) 2022-08-29
CA2933660C (en) 2023-05-09
KR102214694B1 (ko) 2021-02-10
CA2933660A1 (en) 2015-07-02
BR112016014916B1 (pt) 2022-10-04
JP6499183B2 (ja) 2019-04-10
PL3087094T3 (pl) 2022-09-26

Similar Documents

Publication Publication Date Title
NZ722025A (en) Beta-hairpin peptidomimetics as selective elastase inhibitors
MX2016008468A (es) Peptidomimeticos de horquilla beta como inhibidores de elastasa selectivos.
CL2019002056A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)
NZ722603A (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
NZ722403A (en) Pharmaceutical compositions for the treatment of inflammatory disorders
CO2018006299A2 (es) Compuestos novedosos
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
BR112018010933A2 (pt) anticorpos multiespecíficos
MX375674B (es) Compuestos de carboxamida inhibidores de la actividad de cinasa rip2.
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
UA111382C2 (uk) Інгібітори протеїнкінази
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EA201600306A1 (ru) Фунгицидные композиции
MX2015011766A (es) Inhibidores tripeptidicos de la epoxicetona proteasa.
MX362747B (es) Derivado de ácido cicloalquilo, método de preparación del mismo, y aplicación farmacéutica del mismo.
MX2017007607A (es) Inhibidores de necrosis celular y metodos relacionados.
EA201690888A1 (ru) Новые гетероциклические соединения
MX2016009759A (es) Inhibidores de neprilisina.
CY1122747T1 (el) Αντιβιοτικες θεραπειες πεπτιδιων που προερχονται απο νεροβουβαλο
PH12018502242A1 (en) Imidazolone compounds as human neutrophil elastase inhibitors
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
MX357352B (es) Uso de derivados poliaminoisoprenilo en un tratamiento antibiotico o antiseptico.
WO2013123081A3 (en) Use of small molecule inhibitors targeting the interaction between rac gtpase and p67 (phox)
MX2022004806A (es) Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763).

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2020 BY CPA GLOBAL

Effective date: 20191128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2021 BY CPA GLOBAL

Effective date: 20201203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2022 BY DENNEMEYER + CO

Effective date: 20211220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2023 BY DENNEMEYER + CO.

Effective date: 20221220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2024 BY DENNEMEYER AND CO. SARL

Effective date: 20231218

LAPS Patent lapsed